David A. Fidock
David A. Fidock | |
---|---|
University Paris VII | |
Scientific career | |
Fields | Microbiology, immunology |
Institutions |
|
Thesis | Molecular and Immuno-Epidemiological Studies of the Plasmodium falciparum STARP and LSA-1 Antigens Expressed During the Pre-Erythrocytic Stages in Humans (1994) |
Doctoral advisor | Pierre Druilhe |
Website | www |
David A. Fidock (born 8 December 1965), is the CS Hamish Young Professor of Microbiology and Immunology and Professor of Medical Sciences at Columbia University Irving Medical Center in Manhattan.[1][2][3]
Education
Fidock attended the
Career
After his post-doctoral training, Fidock joined the Albert Einstein College of Medicine in New York as an Assistant Professor in the Department of Microbiology and Immunology. In 2007, Fidock became an Associate Professor at Columbia University in the Departments of Microbiology and Immunology and of Medicine (Division of Infectious Diseases).[2] Since 2008, Fidock has been a tenured Professor of Microbiology and Immunology and of Medical Sciences at Columbia.[2] In 2017 he received the C.S. Hamish Young endowed Professorship. From 2008-2023 he served as the Program Director of the NIH T32-funded Graduate Program in Microbiology, Immunology, and Infection. In 2023, he was elected as the incoming President of the American Society of Tropical Medicine and Hygiene.[7]
Research
Fidock's research focuses on the genetic and molecular mechanisms behind
He has published more than 280 papers on malaria, with a current h-index of 97. His work has been cited over 34,000 times. His work has been funded by the NIH, the Bill & Melinda Gates Foundation, the Department of Defense, the Burroughs Wellcome Fund and the Medicines for Malaria Venture.[14][2][8][7][15]
Honors
- 1992 "Bourse Roux" Scholarship, Pasteur Institute, Paris[15]
- 1994 Ph.D. Graduate, Summa cum Laude, University Paris VII/Pasteur Institute, Paris[7][2]
- 2001 New Initiatives in Malaria Research, Burroughs Wellcome Fund[7][8][15]
- 2001 Speaker's Fund in Biomedical Research, New York Academy of Medicine[7][8][15]
- 2001 New Scholar in Global Infectious Disease, Ellison Medical Foundation[7][8][15]
- 2004 Investigator in Pathogenesis of Infectious Disease, Burroughs Wellcome Fund[7][8][15]
- 2014 Recipient of the Bailey K. Ashford Medal for Distinguished Research in Tropical Medicine from the American Society of Tropical Medicine and Hygiene[16][7]
- 2015 Elected to the Council of the American Society of Tropical Medicine and Hygiene[16][7]
- 2016 Elected as a Fellow of the American Society of Tropical Medicine and Hygiene[16][7]
- 2016 Advance Global Australian of the Year in Life Sciences, given by the Australian Prime Minister
- 2020 Recipient, William Trager Medal for transformative research in molecular parasitology, American Society of Tropical Medicine and Hygiene[16][7]
- 2020 Winner of the 2020 Project of the Year from the Medicines for Malaria Venture for critical contribution to malaria drug resistance profiling[14]
- 2023 Elected Member, American Academy of Microbiology[7][8][15]
- 2023 Elected as President of the American Society of Tropical Medicine and Hygiene[16][7]
Publications
- Determinants of piperaquine-resistant malaria in South America. Lancet Infect Dis. (Epub ahead of print.)[17]
- The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistance. Cell Chem Biol (in press).[18]
- Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. Elife 10: e66277.[19]
- Inhibition of resistance-refractory P. falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking antiplasmodial activity. Cell Chem Biol 27: 806-16.[20]
- Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13. PLoS Pathog 16: e1008482.[21]
- Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. PLoS Pathog 15: e1007722.[22]
- Plasmodium falciparum resistance to piperaquine driven by PfCRT. Lancet Infect Dis 19: 1168-9.[23]
- Structure and drug resistance of the Plasmodium falciparum transporter PfCRT. Nature 576: 315-20.[24]
References
- ^ "Faculty - David A. Fidock". Department of Microbiology & Immunology -US. Retrieved 2022-01-04.
- ^ a b c d e "David A. Fidock, PhD". Vagelos College of Physicians and Surgeons. 2017-06-12. Retrieved 2022-01-04.
- ^ "David Fidock". scholar.google.com. Retrieved 2022-01-04.
- ^ a b "David A. Fidock, PhD". Columbia University. 12 June 2017. Retrieved 2022-01-04.
- ^ "David Fidock". Delgeme. Archived from the original on 2022-07-21. Retrieved 2022-01-04.
- ^ "Welcome Message from our President, Dr. Mahalia Desruisseaux" (PDF). ASTMH. 2021.
- ^ a b c d e f g h i j k l m "David Fidock". The Fidock Lab. Retrieved 2023-12-01.
- ^ a b c d e f g "MMV awards Project of the Year 2020 to Professor David Fidock and team for critical contribution to malaria drug resistance profiling | Medicines for Malaria Venture". www.mmv.org. 18 December 2020. Retrieved 2022-01-04.
- PMID 28777791.
- PMID 33479319.
- PMID 34001441.
- PMID 17709280.
- PMID 33479319.
- ^ a b "MMV awards Project of the Year 2020 to Professor David Fidock and team for critical contribution to malaria drug resistance profiling - Medicines for Malaria Venture". www.mmv.org. 18 December 2020. Retrieved 2022-03-16.
- ^ a b c d e f g "David Fidock". Advance The Global Australian Network. Retrieved 2023-12-01.
- ^ a b c d e "astmh.org" (PDF).
- PMID 37858324.
- PMID 34233174.
- PMID 34279219.
- PMID 32359426.
- PMID 32310999.
- PMID 31170268.
- PMID 31657776.
- PMID 31776516.
External links
- David A. Fidock publications indexed by Google Scholar
- Fidock Lab website (www.fidock.org)